Business
CervoMed to Present at the Emerging Growth Conference
BOSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic
About this update from Cervomed Inc.
[{"type":"text","content":"BOSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Matthew Winton, Ph.D., Chief Commercial and Business Officer, will present at the Emerging Growth Conference, being held virtually on Wednesday, October 22, 2025. Presentation DetailsFormat: Corporate PresentationDate: Wednesday, October 22, 2025Time: 11:25 – 11:55 AM ETWebcast Link: https://goto.webcasts.com/starthere.jsp?ei=1717092&tp_key=1ddfafa563&sti=crvo The webcast and replay of the presentation will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/. About CervoMedCervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. The Company’s recently completed Phase 2b trial evaluated neflamapimod in patients with DLB. Investor Contact: PJ KelleherLifeSci [email protected] \nSource: CervoMed Inc.","length":3162,"tagName":"div"}]